Oral absorption of anti- AIDS nucleoside analogues. 3. Regional absorption andin vivo permeability of 2′, 3′ - dideoxyinosine in an intestinal-vascular access port (IVAP) dog model

Pharmacokinetic properties of a novel inosine analog, 4′-cyano-2′-deoxyinosine, after oral administration in rats

“…The half-life (t 1/2 ) of SK14-061a was about 3.6 hr, with a time to reach peak plasma concentration (t max ) value of 1.3 hr. In a previous study, ddI was reported to show site dependent absorption, with a better absorption in the duodenum than in the ileum and colon [ 12 ]. In addition, it was reported that other purine structure-based NAs, ETV, also showed region-specific apparent absorption in the rank order duodenum > jejunum > ileum, with a rapid t max value [ 13 ].…”

Pharmacokinetic properties of a novel inosine analog, 4′-cyano-2′-deoxyinosine, after oral administration in rats

“…The half-life (t 1/2 ) of SK14-061a was about 3.6 hr, with a time to reach peak plasma concentration (t max ) value of 1.3 hr. In a previous study, ddI was reported to show site dependent absorption, with a better absorption in the duodenum than in the ileum and colon [ 12 ]. In addition, it was reported that other purine structure-based NAs, ETV, also showed region-specific apparent absorption in the rank order duodenum > jejunum > ileum, with a rapid t max value [ 13 ].…”

Design of Prodrugs to Enhance Colonic Absorption by Increasing Lipophilicity and Blocking Ionization

“…A preclinical dog colonic absorption model was used to initially evaluate the enhancement of colonic permeation of the prodrugs. Published literature indicates that, in general, the dog model is a good model to predict human colonic absorption [ 22 , 23 , 24 ]. Sutton et al ., shows a good relationship of relative bioavailability in dogs and human following oral and colonic administration for a relatively large number of compounds [ 24 ].…”

Pharmacokinetic properties of a novel inosine analog, 4′-cyano-2′-deoxyinosine, after oral administration in rats

“…The half-life (t 1/2 ) of SK14-061a was about 3.6 hr, with a time to reach peak plasma concentration (t max ) value of 1.3 hr. In a previous study, ddI was reported to show site dependent absorption, with a better absorption in the duodenum than in the ileum and colon [ 12 ]. In addition, it was reported that other purine structure-based NAs, ETV, also showed region-specific apparent absorption in the rank order duodenum > jejunum > ileum, with a rapid t max value [ 13 ].…”

Design of Prodrugs to Enhance Colonic Absorption by Increasing Lipophilicity and Blocking Ionization

“…A preclinical dog colonic absorption model was used to initially evaluate the enhancement of colonic permeation of the prodrugs. Published literature indicates that, in general, the dog model is a good model to predict human colonic absorption [ 22 , 23 , 24 ]. Sutton et al ., shows a good relationship of relative bioavailability in dogs and human following oral and colonic administration for a relatively large number of compounds [ 24 ].…”

Pharmacokinetic properties of a novel inosine analog, 4′-cyano-2′-deoxyinosine, after oral administration in rats

“…The half-life (t 1/2 ) of SK14-061a was about 3.6 hr, with a time to reach peak plasma concentration (t max ) value of 1.3 hr. In a previous study, ddI was reported to show site dependent absorption, with a better absorption in the duodenum than in the ileum and colon [ 12 ]. In addition, it was reported that other purine structure-based NAs, ETV, also showed region-specific apparent absorption in the rank order duodenum > jejunum > ileum, with a rapid t max value [ 13 ].…”

Design of Prodrugs to Enhance Colonic Absorption by Increasing Lipophilicity and Blocking Ionization

“…A preclinical dog colonic absorption model was used to initially evaluate the enhancement of colonic permeation of the prodrugs. Published literature indicates that, in general, the dog model is a good model to predict human colonic absorption [ 22 , 23 , 24 ]. Sutton et al ., shows a good relationship of relative bioavailability in dogs and human following oral and colonic administration for a relatively large number of compounds [ 24 ].…”